Yields soften, but possibility of rising rates cannot be ruled out


Bond And Money Market

We present a matrix detailing some movement in some key market rates (domestic and global) and key events:

Parameters 30-Apr-21 31-Mar-21 30-Apr-20
RBI Repo Rate % 4.00 4.00 4.40
5Y AAA PSU % 5.95 6.14 6.93
1 year CD % 3.90 4.38 4.79
10Y Gsec % 6.03 6.17 6.11
CPI (%) 5.52 5.03 5.84
IIP (FYTD) % -3.58 5.17 2.23
US 10Y % 1.63 1.74 0.64
Dollar Rupee 74.09 73.11 75.10

Source: Bloomberg; Data as on April 30th, 2021

It was a good month for the domestic debt markets as rates softened across the yield curve. The benchmark 10 year Gsec dropped by around 15 bps in the month and similar drop in rates was witnessed in bond rates across the tenor. What helped a soft bias for the rates market, despite an uptick in inflation, was the RBI signaling measures in the form of the launch of GSAP program (announced in the Monetary policy) and the rejection of bids in the GoI auction (without any devolvement). The money markets remained soft as the liquidity conditions continued to remain in a surplus mode.

Looking Ahead
  • The RBI continues to remain the beacon of hope for the domestic debt markets. The surge in pandemic domestically has also put the markets to believe that the MPC will continue to remain dovish as it would continue to focus on growth and would ignore inflation as a transient phenomenon.
  • However, we remain apprehensive of a gradual rate rise as we move through the year. We believe that the markets may stop coat tailing the RBI, and are not ignoring a commodity prices rise induced inflation and a larger borrowing program
  • The possibility of a bear flattening of the yield curve exists with long term rates rising lesser than short term rates
  • Liquidity being in sustained surplus mode, the extreme short end of the yield curve may remain stable.
Scheme Specific Strategies for Debt schemes
  • Mahindra Manulife Low Duration Fund
  • Mahindra Manulife Ultra Short Term Fund
    • The average maturity of the portfolio is around 128 days
    • We will maintain the maturity as we move ahead through the next month
    • The YTM of the portfolio is around 3.87%
    • With surplus liquidity conditions we expect the extreme short end money market rates to remain benign
  • Mahindra Manulife Liquid Fund
    • We continue to maintain a healthy mix of certificate of deposits and commercial papers
    • We will attempt to ensure adequate liquidity, safety and accrual
  • Mahindra Manulife Dynamic Bond Yojana
    • The scheme has been re-categorised from a ‘Credit Risk Fund to a ‘Dynamic Bond’ category scheme
    • The YTM of the portfolio has decreased to around 5.04%.
    • The Modified Duration of the portfolio (MD) is around 1.50
    • Going ahead, we will attempt to increase the MD of the scheme to around the MD of the benchmark through increased exposure to Gilts
    • We are likely to continue with the non AAA credits carrying near term maturities in our portfolio till maturities and consider replacing them preferably with high quality debt instruments.
  • Mahindra Manulife Short Term Fund
    • The YTM of the portfolio is around 5.11 %
    • The Modified duration of the portfolio is close to 1.80
    • The portfolio is almost equally split between money market instruments, bonds and sovereign securities and we may reduce the exposure to sovereign securities as we move ahead.

Time to monitor spread of Covid-19 cases and its potential impact on Indian Economy

Equity Market outlook and overview

We present a summary of changes in key Indian & Global equity indices


S&P BSE Sensex Nifty 50 BSE Midcap BSE Small Cap Nifty Midcap 100 Nifty Small Cap 100 Dow Jones Indus. Avg S&P 500 Index Nasdaq Composite Index
1 Mth Performance -1.47% -0.41% 0.65% 4.94% 2.12% 5.57% 2.71% 5.24% 5.40%
1 Yr Performance 44.68% 48.39% 69.08% 95.19% 79.20% 110.03% 39.14% 43.56% 57.07%

Source: Bloomberg Performance - Absolute returns | Data as on April 30, 2021

Equity Market Update

Indian markets had a volatile month with reasonable swings on both side and ended with marginal loss for Nifty. Mid and Small cap indices fared far better than Nifty as retail participation in markets as well as expectation of cyclical recovery remains high. This is again quite similar to broader trends across the global markets where recovery is broad based. Among large sectors in market; Metals and Pharma gave a sharp positive returns while many other sectors were negative for the month with Auto, Financials, FMCG, Energy, IT underperforming Nifty. FII flows were negative during the month.

Globally, the equity markets continue to remain in bullish mode as the expectations of economic recovery gets stronger along with the rising pace of vaccination. The economic data flow too has entered an extremely favourable phase as disruption during lockdown has now set into the base year. The US Federal Reserve at its meeting during the month, re-iterated that monetary policies are likely to remain benign despite inflationary expectations. Rising commodity prices is a key reason for worries on inflation front. The key arguments for metals being that USA is likely to emerge as a big incremental consumer as the infrastructure spend starts as per President Biden’s plan. Other variables also being the longer term road map of Electric Vehicles roll out that creates its own demand for commodities like Aluminum and Copper.

Indian economy appears to have got into trouble zone with the second phase of covid spreading widely across states. Quite a few states reacted with policy actions to restrict movements. While these steps were not akin to lockdown but in reality the impact has been felt on mobility and business activities across. A nation-wide lockdown while is not announced but many medical professionals and health experts are advising a lockdown to break the chain of spread. It has been a bad month on news flow front especially on inadequate infrastructure; both physical (beds/oxygen etc) as well as soft (medical professionals being over worked and stretched). On positive front, Government relaxed the process for vaccine supply as well as imports and announced aggressive vaccination targets. Hopefully, over next 6 months, a good 40-50% of population (above age group of 18 years) could get vaccinated if all supply dynamics including logistics play out as expected. We hope the covid spread is contained and neither health nor economy reaches crises zone.

There has been some weakness in the trend of normalization and this would lead to downgrades for economy in Q1 of FY22. The corporate results for Q4FY21 have commenced well with no negative surprises from lenders like Banks and NBFCs on the covid phase 1. The early set of results from other sectors too have been in line with expectations. The result season is likely to stretch longer as regulatory compliance has been extended to June 30th for the Q4FY21 results. Without factoring any major impact of covid phase 2, the key challenge for Corporate profitability for FY22 would arise from the impact of commodity costs as well as normalisation of operating costs (in line with normalisation of economic activities). The commentary from corporates would provide some indications on this front.

Looking Ahead

Globally, the vaccination roll out has been aggressive and the re-opening of economy is the focus area for financial markets. The markets are not prepared for any fresh clampdowns on economic activities. In India too, we need to monitor the covid spread for it can really push economic recovery by 6-12 months. We hope that virus spread is contained quickly and there is no damage to fundamental recovery in economic activities.

We continue to monitor economic activities and development on covid spread and policy actions. The management commentary associated with Q4FY21 results would provide some data points to track and analyse.

Risk (Uncertainty in Markets) has its own relationship with Returns and there are perhaps two ways to manage such greed and fear phase. Investors with lumpsum investments could have an asset allocation strategy (equity as a % of portfolio) to try and benefit from greed and fear phases. Alternately, the strategy is to really stick to longer term outlook rather than focusing on 1-2 years volatility. For investors with SIP investments however such phases are not so relevant as investor is still in accumulation phase for wealth creation over the 5-7 years. SIP may be a good alternate to avoid the behavioural traps during the extreme phases of markets. We maintain that Investors use SIP as part of core investment philosophy and use the lumpsum route during the extreme phases to top-up on their SIPs during the fearful times amidst the volatility.

Scheme Specific Strategies for Equity schemes
  • Mahindra Manulife Multi Cap Badhat Yojana
  • Mahindra Manulife Mid Cap Unnati Yojana
  • Mahindra Manulife ELSS Kar Bachat Yojana
  • Mahindra Manulife Rural Bharat and Consumption Yojana
  • Mahindra Manulife Large Cap Pragati Yojana
  • Mahindra Manulife Top 250 Nivesh Yojana
  • Mahindra Manulife Focused Equity Yojana
Scheme Specific Strategies For Hybrid Schemes
  • Mahindra Manulife Equity Savings Dhan Sanchay Yojana
  • Mahindra Manulife Hybrid Equity Nivesh Yojana

    Equity:

    • Portfolio composition would have preference for growth style of investing.
    • Bottom-up approach would be adopted to identify companies that have ability to scale up, gain market share and/or are present in sunrise/high growth sectors.

    Debt:

    • The Modified duration of the portfolio is around 3.40 for the debt portion
    • The current asset allocation has a higher allocation to GoI securities than AAA credits.
What should an investor do?

For investments in debt oriented products:

  • We believe that the investors with a shorter investment horizon may continue investments in ultra-short term and low duration funds
  • For a medium to long term investment horizon and with a suitable risk appetite, an allocation to short term fund and dynamic bond fund merits attention.

For investments in equity oriented products:

  • Our view is that volatility may continue and SIP may be a good way to increase equity market allocations
  • We believe investors with shorter investment horizon and lower risk appetite, may invest in arbitrage fund to hedge against volatility
  • Investors looking to invest for a longer period, can consider SIPs or STPs into focused, multicap or balanced funds based on risk appetite.
  • Investors looking for a better return opportunity and with a suitable risk appetite, may consider part allocation in the mid cap scheme as well.
Scheme Name Product Suitability Riskometer
Mahindra Manulife Overnight Fund
An open ended debt scheme investing in overnight securities
This Product is suitable for investors who are seeking*:
  • To generate reasonable returns with high levels of safety and convenience of liquidity over short term
  • To invest in debt and money market instruments having maturity of upto 1 business day
Mahindra Manulife Arbitrage Yojana
An open ended scheme investing in arbitrage opportunities
This Product is suitable for investors who are seeking*:
  • Income over short term
  • Income through arbitrage opportunities between cash and derivative market and arbitrage opportunities within the derivative segment.
Mahindra Manulife Liquid Fund
An Open Ended Liquid scheme
This Product is suitable for investors who are seeking*:
  • Regular income over short term
  • Investment in money market and debt instruments
Mahindra Manulife Short Term Fund
An open ended short term debt scheme investing in instruments such that the Macaulay duration of the portfolio is between 1 year and 3 years (please refer to page no. 35 of SID)
This Product is suitable for investors who are seeking*:
  • Income over short to medium term.
  • Investment in debt and money market instruments.
Mahindra Manulife Low Duration Fund
An open ended low duration debt scheme investing in instruments such that the Macaulay duration of the Portfolio is between 6 months and 12 months (Please refer page 32 of SID)
This Product is suitable for investors who are seeking*:
  • Regular income over short term
  • Investment in debt and money market instruments
Mahindra Manulife Ultra Short Term Fund
An open ended ultra-short term debt scheme investing in instruments such that the Macaulay duration of the portfolio is between 3 to 6 months (please refer to page no. 32 of SID)
This Product is suitable for investors who are seeking*:
  • Regular Income over short term.
  • Investment in a portfolio of short term debt and money market instruments.
Mahindra Manulife Dynamic Bond Yojana
An open ended debt scheme investing across duration 
This Product is suitable for investors who are seeking*:
  • To generate regular returns and capital appreciation through active management of portfolio
  • Investments in debt & money market
Mahindra Manulife Equity Savings Dhan Sanchay Yojana
An open ended scheme investing in equity, arbitrage and debt
This Product is suitable for investors who are seeking*:
  • Long term capital appreciation and generation of income
  • Investment in equity and equity related instruments, arbitrage opportunities and debt and money market instruments
Mahindra Manulife ELSS Kar Bachat Yojana
An open ended equity linked saving scheme with a statutory lock in of 3 years and tax benefit
This Product is suitable for investors who are seeking*:
  • Long term capital appreciation
  • Investment predominantly in equity and equity related securities
Mahindra Manulife Focused Equity Yojana
An open ended equity scheme investing in maximum 30 stocks across market caps (i.e Multi Cap)
This Product is Suitable for investors who are seeking*
  • Long term capital appreciation
  • Investment in equity and equity related instruments in concentrated profile of maxium 30 stocks across market capitalziation.
Mahindra Manulife Top 250 Nivesh Yojana
Large & Mid Cap Fund - An open ended equity scheme investing in both large cap and mid cap stocks
This Product is suitable for investors who are seeking*:
  • Long term wealth creation and income
  • Investment predominantly in equity and equity related securities of large and Mid cap companies.
Mahindra Manulife Multi Cap Badhat Yojana
Multi Cap Fund- An open ended equity scheme investing across large cap, mid cap, small cap stocks
This Product is suitable for investors who are seeking*:
  • Medium to Long term capital appreciation;
  • Investment predominantly in equity and equity related securities including derivatives.
Mahindra Manulife Mid Cap Unnati Yojana
Mid Cap Fund – An open ended equity scheme predominantly investing in mid cap stocks
This Product is suitable for investors who are seeking*:
  • Long term capital appreciation;
  • Investment predominantly in equity and equity related securities including derivatives of mid cap companies
Mahindra Manulife Large Cap Pragati Yojana
Large Cap Fund - An open ended equity scheme predominantly investing in large cap stocks
This Product is suitable for investors who are seeking*:
  • Long term capital appreciation;
  • Investment predominantly in equity and equity related securities including derivatives of large cap companies.
Mahindra Manulife Hybrid Equity Nivesh Yojana
An open ended hybrid scheme investing predominantly in equity and equity related instruments
This Product is suitable for investors who are seeking*:
  • Long term capital appreciation and generation of income;
  • Investment in equity and equity related instruments and debt and money market instruments
Mahindra Manulife Rural Bharat and Consumption Yojana
An open ended scheme following Rural India theme
This Product is suitable for investors who are seeking*:
  • Long term capital appreciation;
  • Investment predominantly in equity and equity related securities including derivatives of entities engaged in and/ or expected to benefit from the growth in rural India.

* Investors should consult their financial advisers if in doubt about whether the product is suitable for them

The views expressed here in this material are for general information and reading purpose only and do not constitute any guidelines and recommendations on any course of action to be followed by the reader. No representation or warranty is made as to the accuracy, completeness or fairness of the information and opinions contained herein. The views are not meant to serve as a professional guide / investment advice / intended to be an offer or solicitation for the purchase or sale of any financial product or instrument or mutual fund units for the reader. This material has been prepared on the basis of publicly available information, internally developed data and other sources believed to be reliable. While utmost care has been exercised while preparing this material, Mahindra Manulife Investment Management Private Limited (formerly known as Mahindra Asset Management Company Private Limited) (AMC) does not warrant the completeness or accuracy of the information and disclaims all liabilities, losses and damages arising out of the use of this information. The data/statistics given in this material are to explain general market trends in the securities market, it should not be construed as any research report/research recommendation. Readers of this material should rely on information / data arising out of their own investigations and advised to seek independent professional advice and arrive at an informed decision before making any investments. Neither Mahindra Manulife Mutual Fund, the AMC nor Mahindra Manulife Trustee Private Limited (formerly known as Mahindra Trustee Company Private Limited), its directors or associates shall be liable for any damages that may arise from the use of the information contained herein.

Cno.00951

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.